A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01)
A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. Eligible participants will be randomized in a 1:1 ratio to receive either tiragolumab plus atezolizumab or placebo plus atezolizumab.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Queensland
-
Woolloongabba, Queensland, Australia, 4102
- Princess Alexandra Hospital
-
-
Victoria
-
Heidelberg, Victoria, Australia, 3084
- Austin Hospital Olivia Newton John Cancer Centre
-
Melbourne, Victoria, Australia, 3000
- Peter Maccallum Cancer Centre
-
-
-
-
-
Linz, Austria, 4020
- Ordensklinikum Linz Elisabethinen
-
Vienna, Austria, 1140
- Klinik Penzing
-
Vienna, Austria, 1210
- Krankenhaus Nord - Klinik Floridsdorf
-
-
-
-
Rio Grande do Sul
-
Ijuí, Rio Grande do Sul, Brazil, 98700-000
- Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
-
-
São Paulo
-
Barretos, São Paulo, Brazil, 14784-400
- Hospital de Cancer de Barretos
-
-
-
-
-
Beijing, China, 100142
- Beijing Cancer Hospital
-
Changchun, China, 130021
- The First Hospital of Jilin University
-
Chengdu, China, 610041
- West China Hospital, Sichuan University
-
Chongqing, China, 400030
- Chongqing Cancer Hospital
-
Fuzhou, China, 350014
- Fujian Cancer Hospital
-
Haikou, China, 570311
- Hainan General Hospital
-
Hangzhou, China, 310016
- Sir Run Run Shaw Hospital Zhejiang University
-
Harbin, China, 150081
- Harbin Medical University Cancer Hospital
-
Jinan, China, 250013
- Jinan Central Hospital
-
Meizhou, China, 514031
- Meizhou People's Hospital
-
Nanchang, China, 330200
- The 1st Affiliated Hospital of Nanchang Unversity
-
Nantong, China, 226361
- Nantong Tumor Hospital
-
Shanghai, China, 200433
- Shanghai Pulmonary Hospital
-
Shanghai, China, 200032
- Zhongshan Hospital Fudan University
-
Shanghai, China, 200120
- Fudan University Shanghai Cancer Center
-
Wuhan, China, 430022
- Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology
-
Xi'an, China, 710061
- First Affiliated Hospital of Medical College of Xi'an Jiaotong University
-
Zhejiang, China, 310022
- Zhejiang Cancer Hospital
-
-
-
-
-
Frankfurt, Germany, 60488
- Krankenhaus Nordwest
-
Großhansdorf, Germany, 22927
- LungenClinic Großhansdorf GmbH
-
Halle, Germany, 06120
- Krankenhaus Martha-Maria Halle-Doelau gGmbH
-
Immenhausen, Germany, 34376
- Fachklinik für Lungenerkrankungen
-
Löwenstein, Germany, 74245
- SLK Kliniken Heilbronn GmbH, Standort Fachklinik Löwenstein
-
Münster, Germany, 48153
- Gemeinschaftspraxis für Hämatologie und Onkologie
-
Stuttgart, Germany, 70376
- Klinik Schillerhöhe
-
-
-
-
-
Athens, Greece, 185 47
- Metropolitan Hospital
-
Athens, Greece, 104 31
- Sotiria Hospital
-
Larissa, Greece, 411 10
- University Hospital of Larissa
-
Thessaloniki, Greece, 570 01
- Diavalkaniko Hospital
-
-
-
-
-
Budapest, Hungary, 1121
- Orszagos Koranyi TBC es Pulmonologiai Intezet
-
Mátraháza, Hungary, 3233
- Matrai Gyogyintezet
-
Szolnok, Hungary, 5004
- Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház
-
-
-
-
Campania
-
Naples, Campania, Italy, 80131
- Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
-
-
Lazio
-
Rome, Lazio, Italy, 00151
- Azienda Ospedaliera San Camillo Forlanini
-
Rome, Lazio, Italy, 00168
- Policlinico Universitario "Agostino Gemelli"
-
-
Lombardy
-
Milan, Lombardy, Italy, 20141
- Irccs Istituto Europeo di Oncologia (IEO)
-
Monza, Lombardy, Italy, 20900
- Asst Di Monza
-
Rozzano, Lombardy, Italy, 20089
- Istituto Clinico Humanitas
-
-
Piedmont
-
Orbassano, Piedmont, Italy, 10043
- Azienda Sanitaria Ospedaliera S Luigi Gonzaga
-
-
Umbria
-
Perugia, Umbria, Italy, 06156
- Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia
-
-
Veneto
-
Padova, Veneto, Italy, 35128
- IOV - Istituto Oncologico Veneto - IRCCS
-
-
-
-
-
Aichi, Japan, 464-8681
- Aichi Cancer Center
-
Chiba, Japan, 277-8577
- National Cancer Center Hospital East
-
Fukuoka, Japan, 812-8582
- Kyushu University Hospital
-
Miyagi, Japan, 980-0873
- Sendai Kousei Hospital
-
Niigata, Japan, 951-8566
- Niigata Cancer Center Hospital
-
Osaka, Japan, 589-8511
- Kindai University Hospital
-
Osaka, Japan, 541-8567
- Osaka International Cancer Institute
-
Saitama, Japan, 362-0806
- Saitama Cancer Center
-
Sakaishi, Japan, 591-8555
- NHO Kinki-Chuo Chest Medical Center
-
Shizuoka, Japan, 411-8777
- Shizuoka Cancer Center
-
Tokyo, Japan, 104-0045
- National Cancer Center Hospital
-
Tokyo, Japan, 135-8550
- The Cancer Institute Hospital of JFCR
-
-
-
-
Mexico CITY (federal District)
-
México, Mexico CITY (federal District), Mexico, 06100
- Cryptex Investigacion Clinica SA de CV
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 64710
- AVIX Investigación Clínica S.C
-
-
Querétaro
-
Querétaro City, Querétaro, Mexico, 76000
- Cuidados oncologicos
-
-
-
-
-
's-Hertogenbosch, Netherlands, 5223 GZ
- Jeroen Bosch Ziekenhuis
-
Ede, Netherlands, 6716 RP
- Ziekenhuis Gelderse Vallei
-
Leeuwarden, Netherlands, 8934 AD
- Frisius MC Leeuwarden
-
The Hague, Netherlands, 2545 AA
- Hagaziekenhuis, locatie Leyweg
-
-
-
-
-
Arequipa, Peru, 5154
- Instituto Regional de Enfermedades Neoplásicas del Sur
-
Lima, Peru, 15038
- Instituto Nacional de Enfermedades Neoplasicas
-
Lima, Peru, Lima 41
- Clinica Internacional, Sede San Borja
-
San Isidro, Peru, Lima 27
- Clinica Ricardo Palma
-
-
-
-
-
Gda?sk, Poland, 80-214
- Uniwersyteckie Centrum Kliniczne
-
Olsztyn, Poland, 10-357
- Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie
-
Poznan, Poland, 60-569
- Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu
-
-
-
-
Moscow Oblast
-
Moscow, Moscow Oblast, Russia, 143422
- MEDSI Clinical Hospital on Pyatnitsky Highway
-
Moscow, Moscow Oblast, Russia, 105229
- Main Military Clinical Hospital named after N.N. Burdenko
-
-
Sankt-Peterburg
-
Saint Petersburg, Sankt-Peterburg, Russia, 194291
- Leningrad Regional Clinical Hospital
-
Saint Petersburg, Sankt-Peterburg, Russia, 189646
- Institute of Oncology
-
Saint Petersburg, Sankt-Peterburg, Russia, 197089
- St. Petersburg Med Univ
-
Saint Petersburg, Sankt-Peterburg, Russia, 197758
- St. Petersburg Clinical Scientific Center of special services medical assis (oncology)
-
-
-
-
-
Belgrade, Serbia, 11000
- Clinical Center of Serbia
-
Belgrade, Serbia, 11080
- University Hospital Medical Center Bezanijska kosa
-
-
-
-
-
Cheongju-si, South Korea, 28644
- Chungbuk National University Hospital
-
Gyeonggi-do, South Korea, 13620
- Seoul National University Bundang Hospital
-
Gyeonggi-do, South Korea, 16499
- Ajou University Medical Center
-
Incheon, South Korea, 21565
- Gachon University Gil Medical Center
-
Jeollanam-do, South Korea, 58128
- Chonnam National University Hwasun Hospital
-
Seoul, South Korea, 03080
- Seoul National University Hospital
-
Seoul, South Korea, 05505
- Asan Medical Center
-
Seoul, South Korea, 03722
- Severance Hospital, Yonsei University Health System
-
Seoul, South Korea, 08308
- Korea University Guro Hospital
-
Seoul, South Korea, 6351
- Samsung Medical Center
-
Seoul, South Korea, 03181
- Kangbuk Samsung Medical Center
-
Suwon, South Korea, 442-723
- St. Vincent's Hospital
-
-
-
-
-
Madrid, Spain, 28041
- Hospital 12 de Octubre
-
Madrid, Spain, 28222
- Hospital Universitario Puerta de Hierro - Majadahonda
-
Madrid, Spain, 41013
- Hospital Universitario Virgen del Rocío
-
Málaga, Spain, 29010
- Hospital Regional Universitario de Malaga
-
Zaragoza, Spain, 50009
- Hosp Clinico Univ Lozano Blesa
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- Hospital Universitario Germans Trias i Pujol
-
-
-
-
-
Bern, Switzerland, 3010
- Inselspital Bern
-
Lausanne, Switzerland, 1011
- CHUV
-
Sankt Gallen, Switzerland, 9000
- HOCH Health Ostschweiz, Kantonsspital St. Gallen
-
-
-
-
-
Guishan Dist., Taiwan, 33305
- Chang Gung Memorial Hospital - Linkou Branch
-
Kaohsiung City, Taiwan, 83301
- Kaohsiung Chang Gung Memorial Hospital
-
Kaohsiung City, Taiwan, 807
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
New Taipei City, Taiwan, 23561
- Taipei Medical University ?Shuang Ho Hospital
-
Taichung, Taiwan, 407
- Taichung Veterans General Hospital
-
Tainan, Taiwan, 704
- National Cheng Kung Uni Hospital
-
Taipei, Taiwan, 112
- Taipei Veterans General Hospital
-
Zhongzheng Dist., Taiwan, 10048
- National Taiwan University Hospital
-
-
-
-
-
Bangkok, Thailand, 10330
- Chulalongkorn Hospital
-
Bangkok, Thailand, 10400
- Ramathibodi Hospital
-
Bangkok, Thailand, 10700
- Faculty of Med. Siriraj Hosp.
-
Songkhla, Thailand, 90110
- Songklanagarind Hospital
-
-
-
-
-
Adana, Turkey (Türkiye), 01120
- Adana Baskent University Hospital
-
Ankara, Turkey (Türkiye), 06100
- Hacettepe University Medical Faculty
-
Istanbul, Turkey (Türkiye), 34098
- Istanbul University Cerrahpasa Faculty of Medicine
-
Izmir, Turkey (Türkiye), 35110
- Izmir Dr. Suat Seren Gogus Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi
-
Kadiköy, Turkey (Türkiye), 34722
- Goztepe Prof.Dr. Suleyman Yalcin City Hospital
-
Malatya, Turkey (Türkiye), 44280
- Inonu University Medical Faculty of Medicine
-
-
-
-
-
Kryvyi Rih, Ukraine, 50048
- ME Kryviy Rih Oncology Dispensary of Dnipropetrovs?k Regional Council
-
Uzhhorod, Ukraine, 88000
- Uzhgorod Nat. University Central Municip Hosp
-
-
-
-
Colorado
-
Denver, Colorado, United States, 80220
- Rocky Mountain Cancer Center - Denver
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Yale Cancer Center
-
-
Florida
-
St. Petersburg, Florida, United States, 33705
- SCRI Florida Cancer Specialists North
-
Tallahassee, Florida, United States, 32308
- SCRI Florida Cancer Specialists PAN
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55102
- US oncology research at Minnesota Oncology
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- SCRI Oncology Partners
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Virginia Cancer Specialists (Fairfax) - USOR
-
Salem, Virginia, United States, 24153
- Onc & Hem Assoc SW Virginia
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Histologically or cytologically documented locally advanced or recurrent NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or metastatic Stage IV non-squamous or squamous NSCLC
- No prior systemic treatment for metastatic NSCLC
- High tumor tissue PD-L1 expression
- Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
- Adequate hematologic and end-organ function
- For participants enrolled in the extended China enrollment phase: current resident of mainland China or Taiwan and of Chinese ancestry.
Exclusion Criteria:
- Known mutation in the EGFR gene or an ALK fusion oncogene
- Symptomatic, untreated, or actively progressing central nervous system metastases
- Active or history of autoimmune disease or immune deficiency
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
- Malignancies other than NSCLC within 5 years, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
- Severe infection within 4 weeks prior to initiation of study treatment
- Positive test result for human immunodeficiency virus (HIV)
- Active hepatitis B or hepatitis C
- Treatment with investigational therapy within 28 days prior to initiation of study treatment
- Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-CTLA-4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies
- Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug elimination half-lives prior to initiation of study treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Tiragolumab + Atezolizumab
Participants will receive atezolizumab followed by tiragolumab every 3 weeks (Q3W) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity. |
Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
Other Names:
Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Other Names:
|
|
Placebo Comparator: Placebo + Atezolizumab
Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity. |
Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
Other Names:
Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Global Cohort: Investigator-assessed Progression-free Survival (PFS) After Randomization According to RECIST v1.1 in the Primary Analysis Set (PAS)
Time Frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
|
PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the PAS. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm) or unequivocal progression of existing non-target lesions. Kaplan-Meier (K-M) method was used to estimate the median PFS. |
From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
|
|
China Cohort: Investigator-assessed PFS After Randomization According to RECIST v1.1 in the PAS
Time Frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
|
PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the PAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS. |
From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
|
|
Global Cohort: Overall Survival (OS) in the PAS
Time Frame: From randomization to death from any cause (up to approximately 54.7 months)
|
OS was defined as the time from randomization to death from any cause in the PAS. K-M method was used to estimate the median OS. |
From randomization to death from any cause (up to approximately 54.7 months)
|
|
China Cohort: OS in the PAS
Time Frame: From randomization to death from any cause (up to approximately 49.1 months)
|
OS was defined as the time from randomization to death from any cause in the PAS. K-M method was used to estimate the median OS. |
From randomization to death from any cause (up to approximately 49.1 months)
|
|
Global Cohort: Number of Participants With Adverse Events (AEs)
Time Frame: Up to 65.1 months
|
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to 65.1 months
|
|
China Cohort: Number of Participants With AEs
Time Frame: Up to 49.3 months
|
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to 49.3 months
|
|
Global Cohort: Number of Participants With Cytokine Release Syndrome (CRS), With Severity Determined by American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale
Time Frame: Up to 65.1 months
|
CRS was defined as supraphysiologic response following administration of immune therapy that results in activation/engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms include fever, hypotension, hypoxia, & end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension & hypoxia; Grade 2: fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive-pressure; Grade 5: death due to CRS. |
Up to 65.1 months
|
|
China Cohort: Number of Participants With CRS, With Severity Determined by ASTCT Consensus Grading Scale
Time Frame: Up to 49.3 months
|
CRS was defined as supraphysiologic response following administration of immune therapy that results in activation/engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms include fever, hypotension, hypoxia, & end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension & hypoxia; Grade 2: fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive-pressure; Grade 5: death due to CRS. |
Up to 49.3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Global Cohort: Investigator-assessed PFS According to RECIST v1.1 in the Secondary Analysis Set (SAS)
Time Frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
|
PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the SAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS. |
From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
|
|
China Cohort: Investigator-assessed PFS According to RECIST v1.1 in the SAS
Time Frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
|
PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the SAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS. |
From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
|
|
Global Cohort: OS in the SAS
Time Frame: From randomization to death from any cause (up to approximately 54.7 months)
|
OS was defined as the time from randomization to death from any cause in the SAS. K-M method was used to estimate the median OS. |
From randomization to death from any cause (up to approximately 54.7 months)
|
|
China Cohort: OS in the SAS
Time Frame: From randomization to death from any cause (up to approximately 49.1 months)
|
OS was defined as the time from randomization to death from any cause in the SAS. K-M method was used to estimate the median OS. |
From randomization to death from any cause (up to approximately 49.1 months)
|
|
Global Cohort: Investigator-assessed Confirmed Objective Response Rate (ORR) According to RECIST v1.1 in the PAS
Time Frame: Up to approximately 54.6 months
|
Confirmed ORR was defined as the percentage of participants with a confirmed objective response (OR), characterized by either a complete response (CR) or a partial response (PR), on 2 consecutive occasions ≥ 4 weeks apart, as determined by the investigator per RECIST v1.1 in the PAS. CR was defined as the disappearance of all target and non-target lesions & normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off. |
Up to approximately 54.6 months
|
|
China Cohort: Investigator-assessed Confirmed ORR According to RECIST v1.1 in the PAS
Time Frame: Up to 49.3 months
|
Confirmed ORR was defined as the percentage of participants with a confirmed OR, characterized by either a CR or a PR, on 2 consecutive occasions ≥ 4 weeks apart, as determined by the investigator per RECIST v1.1 in the PAS. CR was defined as the disappearance of all target and non-target lesions & normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off. |
Up to 49.3 months
|
|
Global Cohort: Investigator-assessed Duration of Response (DOR) According to RECIST v1.1 for Participants With Confirmed ORR in the PAS
Time Frame: From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 54.6 months)
|
DOR for participants with confirmed ORR was defined as time from first occurrence of confirmed OR (CR or PR) to PD, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurred first in PAS. CR was defined as disappearance of all target & non-target lesions & normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in SOD of all target lesions, taking as reference baseline SOD, in absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD at prior timepoints (including baseline). Additionally, SOD must also demonstrate absolute increase of ≥5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median DOR. |
From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 54.6 months)
|
|
China Cohort: Investigator-assessed DOR According to RECIST v1.1 for Participants With Confirmed ORR in the PAS
Time Frame: From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to 49.3 months)
|
DOR for participants with confirmed ORR was defined as time from first occurrence of confirmed OR (CR or PR) to PD, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurred first in PAS. CR was defined as disappearance of all target & non-target lesions & normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in SOD of all target lesions, taking as reference baseline SOD, in absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD at prior timepoints (including baseline). Additionally, SOD must also demonstrate absolute increase of ≥5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median DOR. |
From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to 49.3 months)
|
|
Global Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS
Time Frame: At Months 6 and 12
|
PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the PAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off. |
At Months 6 and 12
|
|
China Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS
Time Frame: At Months 6 and 12
|
PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the PAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off. |
At Months 6 and 12
|
|
Global Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS
Time Frame: At Months 6 and 12
|
PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the SAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off. |
At Months 6 and 12
|
|
China Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS
Time Frame: At Months 6 and 12
|
PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the SAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off. |
At Months 6 and 12
|
|
Global Cohort: OS Rate at 12 Months and 24 Months in the PAS
Time Frame: At Months 12 and 24
|
OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the PAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off. |
At Months 12 and 24
|
|
China Cohort: OS Rate at 12 Months and 24 Months in the PAS
Time Frame: At Months 12 and 24
|
OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the PAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off. |
At Months 12 and 24
|
|
Global Cohort: OS Rate at 12 Months and 24 Months in the SAS
Time Frame: At Months 12 and 24
|
OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the SAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off. |
At Months 12 and 24
|
|
China Cohort: OS Rate at 12 Months and 24 Months in the SAS
Time Frame: At Months 12 and 24
|
OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the SAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off. |
At Months 12 and 24
|
|
Global Cohort: Time to Confirmed Deterioration (TTCD) in Participant-reported Physical Functioning (PF), as Measured by European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) in the PAS
Time Frame: Up to approximately 54.6 months
|
TTCD was defined as the time from randomization to first confirmed clinically meaningful deterioration (CCMD). EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), global health status (GHS)/quality-of-life (QoL), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). Functioning was scored on 4-point scale: 1=Not at all to 4=Very much. Scores were linearly transformed to range of 0-100. High score for PF scale=high/healthy level of functioning. CCMD=Clinically meaningful decrease (≥10 points) from baseline in PF score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD. |
Up to approximately 54.6 months
|
|
China Cohort: TTCD in Participant-reported PF, as Measured by EORTC QLQ-C30 in the PAS
Time Frame: Up to approximately 49.3 months
|
TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). Functioning was scored on 4-point scale: 1=Not at all to 4=Very much. Scores were linearly transformed to range of 0-100. High score for PF scale=high/healthy level of functioning. CCMD=Clinically meaningful decrease (≥10 points) from baseline in PF score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD. |
Up to approximately 49.3 months
|
|
Global Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS
Time Frame: Up to approximately 54.6 months
|
TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). GHS/QoL questions were scored on 7-point scale: 1=Very poor to 7=Excellent. Scores were linearly transformed to range of 0-100. High score for GHS/QoL scale=better health-related quality-of-life (HRQoL). CCMD=Clinically meaningful decrease (≥10 points) from baseline in GHS/QoL score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD. |
Up to approximately 54.6 months
|
|
China Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS
Time Frame: Up to approximately 49.3 months
|
TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). GHS/QoL questions were scored on 7-point scale: 1=Very poor to 7=Excellent. Scores were linearly transformed to range of 0-100. High score for GHS/QoL scale=better HRQoL. CCMD=Clinically meaningful decrease (≥10 points) from baseline in GHS/QoL score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD. |
Up to approximately 49.3 months
|
|
Global Cohort: Serum Concentration of Tiragolumab at Specified Timepoints
Time Frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-end of infusion (EOI) on Day 1 of Cycle 1; Treatment discontinuation (TD) visit (up to approximately 54.6 months) (1 Cycle=21 days)
|
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-end of infusion (EOI) on Day 1 of Cycle 1; Treatment discontinuation (TD) visit (up to approximately 54.6 months) (1 Cycle=21 days)
|
|
|
China Cohort: Serum Concentration of Tiragolumab at Specified Timepoints
Time Frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
|
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
|
|
|
Global Cohort: Serum Concentration of Atezolizumab at Specified Timepoints
Time Frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 54.6 months) (1 Cycle=21 days)
|
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 54.6 months) (1 Cycle=21 days)
|
|
|
China Cohort: Serum Concentration of Atezolizumab at Specified Timepoints
Time Frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
|
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
|
|
|
Global Cohort: Number of Participants With Anti-drug Antibodies (ADAs) to Tiragolumab
Time Frame: Up to approximately 54.6 months
|
Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here. |
Up to approximately 54.6 months
|
|
China Cohort: Number of Participants With ADAs to Tiragolumab
Time Frame: Up to approximately 49.3 months
|
Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here. |
Up to approximately 49.3 months
|
|
Global Cohort: Number of Participants With ADAs to Atezolizumab
Time Frame: Up to approximately 54.6 months
|
Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here. |
Up to approximately 54.6 months
|
|
China Cohort: Number of Participants With ADAs to Atezolizumab
Time Frame: Up to approximately 49.3 months
|
Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here. |
Up to approximately 49.3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Clinical Trial, Hoffmann-La Roche
Publications and helpful links
General Publications
- Peters S, Herbst R, Horinouchi H, Paz-Ares L, Johnson M, Solomon BJ, Gumus M, Erman M, Bondarenko I, Kim DW, Felip E, Morabito A, Bryl M, Urban L, Nosaki K, Reck M, Meng R, Stroud C, Kundu P, Wen X, Patil NS, Huang M, Troutman S, Matheny C, Cho BC. SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer. J Clin Oncol. 2026 Sep;44(25):2400-2408. doi: 10.1200/JCO-25-02777. Epub 2026 Jul 27.
- Beaufils A, De Martino J, Jiang X, Blanchard T, Fraunhoffer N, Mendes D, Pignolet C, Bourega T, Meneghetti AR, Sainath S, Albuquerque M, Colnot N, Tihy M, Turpin A, Ben Abdelghani M, Wei A, Mitry E, Lecomte T, Biagi J, Artru P, Evesque L, Lambert A, Renouf DJ, Mauduit M, Dusetti NJ, Hammel P, Conroy T, Bachet JB, de Mestier L, Rebours V, Cros J, Kather JN, Nicolle R. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. J Clin Oncol. 2026 Sep 10;44(26):2507-2516. doi: 10.1200/JCO-26-00327. Epub 2026 Jul 27.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GO41717
- 2019-002925-31 (EudraCT Number)
- 2019 (U.S. NIH Grant/Contract)
- 2022-502482-17-00 (Ctis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.